Raymond James Financial Services Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,236	Closed	-$585K	–	3539
2024 Q2	$585K	Sell	14,236 -1,407	-9%	-$60.1K	﹤0.01%	2418
2024 Q1	$730K	Sell	15,643 -3,935	-20%	-$186K	﹤0.01%	2256
2023 Q4	$936K	Sell	19,578 -2,530	-11%	-$98.1K	﹤0.01%	2020
2023 Q3	$788K	Buy	22,108 +12,403	+128%	+$491K	﹤0.01%	2045
2023 Q2	$448K	Buy	+9,705	New	+$450K	﹤0.01%	2407
2019 Q2	–	Sell	-2,929	Closed	-$203K	–	2910
2019 Q1	$203K	Buy	+2,929	New	+$167K	﹤0.01%	2493
2016 Q4	–	Sell	-8,350	Closed	-$592K	–	2422
2016 Q3	$592K	Buy	+8,350	New	+$533K	0.01%	1405

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James Financial Services Advisors's RARE Position: Q3 2024 in Review

Raymond James Financial Services Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2024, closing a stake of 14,236 shares — an estimated $585K sold.

Raymond James Financial Services Advisors first reported a position in RARE in Q3 2016 and held it in 7 quarters. The position peaked at $936K in Q4 2023. 301 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

Raymond James Financial Services Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Raymond James Financial Services Advisors sold 14,236 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $585K.
Raymond James Financial Services Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 7 quarters.
Raymond James Financial Services Advisors's Ultragenyx Pharmaceutical position peaked at $936K in Q4 2023.
301 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.